全文获取类型
收费全文 | 18307篇 |
免费 | 1623篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 170篇 |
儿科学 | 538篇 |
妇产科学 | 391篇 |
基础医学 | 2379篇 |
口腔科学 | 566篇 |
临床医学 | 2149篇 |
内科学 | 3761篇 |
皮肤病学 | 231篇 |
神经病学 | 1732篇 |
特种医学 | 604篇 |
外国民族医学 | 3篇 |
外科学 | 2074篇 |
综合类 | 392篇 |
一般理论 | 14篇 |
预防医学 | 1878篇 |
眼科学 | 361篇 |
药学 | 1403篇 |
中国医学 | 10篇 |
肿瘤学 | 1301篇 |
出版年
2021年 | 307篇 |
2020年 | 211篇 |
2019年 | 310篇 |
2018年 | 336篇 |
2017年 | 262篇 |
2016年 | 291篇 |
2015年 | 310篇 |
2014年 | 461篇 |
2013年 | 585篇 |
2012年 | 917篇 |
2011年 | 934篇 |
2010年 | 522篇 |
2009年 | 439篇 |
2008年 | 816篇 |
2007年 | 824篇 |
2006年 | 828篇 |
2005年 | 777篇 |
2004年 | 780篇 |
2003年 | 723篇 |
2002年 | 626篇 |
2001年 | 603篇 |
2000年 | 598篇 |
1999年 | 512篇 |
1998年 | 200篇 |
1997年 | 151篇 |
1996年 | 160篇 |
1995年 | 197篇 |
1994年 | 158篇 |
1993年 | 165篇 |
1992年 | 456篇 |
1991年 | 420篇 |
1990年 | 427篇 |
1989年 | 406篇 |
1988年 | 340篇 |
1987年 | 333篇 |
1986年 | 286篇 |
1985年 | 284篇 |
1984年 | 208篇 |
1983年 | 203篇 |
1982年 | 154篇 |
1981年 | 127篇 |
1980年 | 130篇 |
1979年 | 213篇 |
1978年 | 148篇 |
1977年 | 135篇 |
1976年 | 148篇 |
1974年 | 143篇 |
1973年 | 160篇 |
1972年 | 136篇 |
1970年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Matthew C. Phillips Laura Sarff Josh Banerjee Chase Coffey Paul Holtom Steve Meurer Noah Wald-Dickler Brad Spellberg 《Journal of medical virology》2022,94(1):318-326
When hospitals first encountered coronavirus disease 2019 (COVID-19), there was a dearth of therapeutic options and nearly 1 in 3 patients died from the disease. By the summer of 2020, as deaths from the disease declined nationally, multiple single-center studies began to report declining mortality of patients with COVID-19. To evaluate the effect of COVID-19 on hospital-based mortality, we searched the Vizient Clinical Data Base for outcomes data from approximately 600 participating hospitals, including 130 academic medical centers, from January 2017 through December 2020. More than 32 million hospital admissions were included in the analysis. After an initial spike, mortality from COVID-19 declined in all regions of the country to under 10% by June 2020 and remained constant for the remainder of the year. Despite this, inpatient, all-cause mortality has increased since the beginning of the pandemic, even those without respiratory failure. Inpatient mortality has particularly increased in elderly patients and in those requiring intubation for respiratory failure. Since June 2020, COVID-19 kills one in every 10 patients admitted to the hospital with this diagnosis. The addition of this new disease has raised overall hospital mortality especially those who require intubation for respiratory failure. 相似文献
2.
Rian M. Hasson Kayla A. Fay Joseph D. Phillips Timothy M. Millington David J. Finley 《American journal of surgery》2021,221(4):725-730
BackgroundRural populations face many health disadvantages compared to urban areas. There is a critical need to better understand the current lung cancer screening landscape in these communities to identify targeted areas to improve the impact of this proven tool.MethodsData from the County Health Rankings of New Hampshire and Vermont was reviewed for population density, distribution of adult smokers, and level of education compared to the distribution of Lung Cancer Screening Facilities throughout these two states.ResultsScreening programs in southern counties of Vermont with lower levels of education have decreased access. In New Hampshire, there are no programs within 30 miles of the areas with the largest distribution of smokers, and decreased access in some areas with the lowest levels of education.ConclusionsImproving equitable access to high-quality screening services in rural regions and the creation of targeted interventions to address decreased access in areas of high tobacco use and low education is vital to decreasing the incidence of latestage presentations of lung cancer within these populations. 相似文献
3.
4.
Alyssa N. Ball Jennifer N. Phillips C. Wayne McIlwraith Christopher E. Kawcak Richard J. Samulski Laurie R. Goodrich 《Journal of orthopaedic research》2019,37(6):1310-1317
Optimizing the environment of complex bone healing and improving treatment of catastrophic bone fractures and segmental bone defects remains an unmet clinical need both human and equine veterinary medical orthopaedics. The objective of this study was to determine whether scAAV‐equine‐BMP‐2 transduced cells would induce osteogenesis in equine bone marrow derived mesenchymal stem cells (BMDMSCs) in vitro, and if these cells could be cryopreserved in an effort to osteogenically prime them as an “off‐the‐shelf” gene therapeutic approach for fracture repair. Our study found that transgene expression is altered by cell expansion, as would be expected by a transduction resulting in episomal transgene expression, and that osteoinductive levels could still be achieved 5 days after recovery, and protein expression would continue up to 14 days after transduction. This is the first evidence that cryopreservation of genetically modified BMDMSCs would not alter the osteoinductive potential or clinical use of allogeneic donor cells in cases of equine fracture repair. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1310–1317, 2019. 相似文献
5.
6.
7.
8.
Nicholas S. Phillips Yin Ting Cheung John O. Glass Matthew A. Scoggins Wei Liu Robert J. Ogg Daniel A. Mulrooney Ching‐Hon Pui Leslie L. Robison Wilburn E. Reddick Melissa M. Hudson Kevin R. Krull 《Pediatric blood & cancer》2020,67(3)
Survivors of childhood acute lymphoblastic leukemia (ALL) treated with chemotherapy only are at risk for neurocognitive impairment. Regions of interest were identified a priori based on glucocorticoid receptor distribution, and sex‐stratified multivariable linear regression models were used to test associations between brain MRI morphology and total number of intrathecal injections, and serum concentration of dexamethasone and methotrexate. Compared with controls, ALL survivors have persistently smaller volumes in the bilateral cerebellum (P < 0.005), hippocampal subregions (P < 0.03), temporal lobe regions (P < 0.03), frontal lobe regions (P < 0.04), and parietal lobe regions (precuneus; P < 0.002). Long‐term problems with learning may be related to residual posttreatment brain differences. 相似文献
9.
10.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献